Evidence-Based Medicine Guidelines
Fondaparinux for acute coronary syndromes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Fondaparinux for Acute Coronary Syndromes." Evidence-Based Medicine Guidelines, John Wiley & Sons, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/450597/all/Fondaparinux_for_acute_coronary_syndromes.
Fondaparinux for acute coronary syndromes. Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. https://evidence.unboundmedicine.com/evidence/view/EBMG/450597/all/Fondaparinux_for_acute_coronary_syndromes. Accessed March 9, 2025.
Fondaparinux for acute coronary syndromes. (2025). In Evidence-Based Medicine Guidelines. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/EBMG/450597/all/Fondaparinux_for_acute_coronary_syndromes
Fondaparinux for Acute Coronary Syndromes [Internet]. In: Evidence-Based Medicine Guidelines. John Wiley & Sons; 2025. [cited 2025 March 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/450597/all/Fondaparinux_for_acute_coronary_syndromes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Fondaparinux for acute coronary syndromes
ID - 450597
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/450597/all/Fondaparinux_for_acute_coronary_syndromes
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
